Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20415259 | 0.89 | OPRK1 (0.46) | OPRK1SMN1; SMN2HPGDMAPTALDH1A1 | |
| SCHEMBL20415346 | 0.88 | NTSR1 (0.45) | OPRK1HPGDMAPTALDH1A1CES2 | |
| SCHEMBL20415215 | 0.87 | DRD2 (0.42) | OPRK1SMN1; SMN2ALDH1A1TDP1DRD4 | |
| SCHEMBL20415250 | 0.85 | SMN1; SMN2 (0.47) | OPRK1SMN1; SMN2MAPTHTR1AALDH1A1 | |
| SCHEMBL20415216 | 0.82 | OPRK1 (0.56) | OPRK1SMN1; SMN2MAPTCHRM1HTR1A | |
| SCHEMBL20415165 | 0.77 | HPGD (0.53) | SMN1; SMN2HPGDMAPTCHRM1GAA | |
| SCHEMBL29073232 | 0.76 | CES2 (0.55) | SMN1; SMN2MAPTALDH1A1CES2CES1 | |
| SCHEMBL11099529 | 0.75 | CA12 (0.48) | SMN1; SMN2MAPTALDH1A1TDP1CES2 | |
| SCHEMBL20415230 | 0.74 | CES2 (0.53) | SMN1; SMN2MAPTALDH1A1CES2CES1 | |
| SCHEMBL20415256 | 0.74 | EGFR (0.49) | SMN1; SMN2MAPTGAAALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| WO-2020205470-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2018136792-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | AR, BRDT, NR5A1 | OPRK1 2415/4885SMN1; SMN2 4437/4885HPGD 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.